Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease

Published:2019-01 Issue:1 Volume:5 Page:164-174
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Ballard Clive¹,Atri Alireza²³,Boneva Neli⁴,Cummings Jeffrey L.⁵,Frölich Lutz⁶,Molinuevo José Luis⁷⁸,Tariot Pierre N.⁹,Raket Lars Lau⁴

Affiliation:

1. University of Exeter Medical SchoolExeterUK

2. Banner Sun Health Research InstituteSun CityAZUSA

3. Brigham and Women's Hospital and Harvard Medical SchoolBostonMAUSA

4. H. Lundbeck A/SValbyDenmark

5. Cleveland Clinic Lou Ruvo Center for Brain HealthLas VegasNVUSA

6. Central Institute of Mental HealthMedical Faculty MannheimUniversity of HeidelbergHeidelbergGermany

7. Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPSHospital Clinic i UniversitariBarcelonaSpain

8. Barcelonaβeta Brain Research CenterPasqual Maragall FoundationBarcelonaSpain

9. Banner Alzheimer's InstitutePhoenixAZUSA

Funder

Acadia

American College of Radiology

AbbVie

Avid

Biogen

Lilly

Lundbeck

Merck

vTV Therapeutics

Teva

NIGMS

AstraZeneca

Avanir

Cognoptix

H. Lundbeck A/S

Merck and Company

Takeda

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.trci.2019.04.001

Reference34 articles.

1. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

2. Back to the future: Alzheimer's disease heterogeneity revisited

3. Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses

4. High Degree of Heterogeneity in Alzheimer's Disease Progression Patterns

5. Alzheimer's disease drug development pipeline: 2018

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Care partner‐informed meaningful change thresholds for the Clinical Dementia Rating‐Sum of Boxes for trials of early Alzheimer's disease;Alzheimer's & Dementia;2024-07-17

2. Disease progression modeling with temporal realignment: An emerging approach to deepen knowledge on chronic diseases;Pharmacology & Therapeutics;2024-07

3. The criteria used to rule out mild cognitive impairment impact dementia incidence rates in subjective cognitive decline;Alzheimer's Research & Therapy;2024-06-28

4. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry;JAMA Neurology;2023-12-01

5. Decision making in clinical trials: Interim analyses, innovative design, and biomarkers;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3